The prolific company creator is staking $50 million on AI drug discovery for cancer and immune diseases, launching a biotech ...

The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, ...

The plans, if implemented, would result in the layoff of about 365 employees. Galapagos said it will still entertain ...

The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Investors reacted positively to news that the company was using a $50 million private placement to help fund a Phase 3 study.

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.

Cost Plus Drugs is sharing pricing data with TrumpRx, the administration’s new direct-to-consumer prescription drug website ...

In an industry where speed and precision can directly affect patient outcomes, pharma companies are under pressure to ...

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

A gene therapy for hearing loss, an experimental pancreatic cancer treatment and seven other medications have been chosen as the first recipients of a new voucher the Food and Drug Administration is ...